NASDAQ$PLXS

Plexus Corp · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Announced fiscal third quarter financial results.

Plexus reported fiscal third quarter revenue of $814 million and GAAP diluted EPS of $0.95. Revenue met the high end of revised expectations. Strong business development performance continued with 31 new manufacturing programs won.

  • Fiscal third quarter 2021 revenue was $814 million.
  • GAAP diluted EPS was $0.95, including $0.04 of restructuring charges and $0.21 of stock-based compensation expense.
  • Won 31 manufacturing programs during the quarter representing approximately $275 million in annualized revenue when fully ramped into production.
  • Trailing four quarter wins total a record $1.1 billion in annualized revenue when fully ramped into production.

Headline financials

Total Revenue

$842M

Previous: $880M-4.3%
EPS (adj)

$0.99

Previous: $1.20-17.5%
ROIC

15.9%

Previous: 12.9%+23.3%
Economic return

7.8%

Previous: 4.1%+90.2%
Capital Expenditures

-$34.4M

Previous: -$41.2M+16.6%
Free Cash Flow

-$6.78M

Previous: -$5.38M-25.9%
Net Income

$27.6M

Previous: $35.8M-23.0%
Operating Income

$36.4M

Previous: $45.9M-20.7%
Gross Profit

$74.1M

Previous: $82.9M-10.7%
Cash & Equivalents

$303M

Previous: $297M+2.3%
Total Assets

$2.32B

Previous: $2.29B+1.4%
Stock-Based Comp

$6.23M

Previous: $6.54M-4.8%

Revenue & EPS history

Plexus · Revenue · Quarterly

$842M

Q3 2021-4.3%vs Q3 2020
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Plexus · $766M total across 2 segments · Q3 2021

  • Asia-Pacific
    $447M-7.3%
  • Americas
    $319M+4.2%

Forward guidance

Plexus is guiding fiscal fourth quarter revenue of $875 to $915 million, GAAP operating margin of 4.8 to 5.2% and GAAP EPS of $1.13 to $1.29.

Tailwinds

  • Expect that vaccination efforts, coupled with the productivity improvements implemented by regional leadership team, will allow Penang operations to function closer to typical levels of manufacturing output during the fiscal fourth quarter despite ongoing workforce curtailment guidelines.
  • Ongoing recovery in equipment used in elective medical procedures
  • Improving commercial aerospace market
  • Sustained program win strength inclusive of new customer engagements
  • Support of secular growth markets, including warehouse and factory automation, robotic assisted surgery and commercial space

Headwinds

  • Guidance assumes that supply chain constraints and COVID-19 do not materially impact end markets or operations beyond what is already anticipated.
  • Evolving effect of COVID-19 on employees, customers, suppliers, and logistics providers, including the impact of governmental actions being taken to curtail the spread of the virus, particularly in the key geography of Malaysia.
  • Effects of shortages and delays in obtaining components as a result of economic cycles, natural disasters or otherwise
  • Risk of customer delays, changes, cancellations or forecast inaccuracies in both ongoing and new programs
  • Lack of visibility of future orders, particularly in view of changing economic conditions

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.1%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+2.5%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+13.2%

Q1 2016

Best reaction

-18.1%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+2.7%+5.8%+7.1%
Q1 2026+9.3%+12.7%+7.3%
Q4 2025+2.8%-1.7%-5.2%
Q2 2025-1.4%-1.1%+1.9%
Q1 2025-10.1%-15.2%-19.4%
Q4 2024+7.5%+6.3%+20.2%
Q3 2024+9.0%+6.3%+7.7%
Q2 2024+2.6%+5.9%+17.3%
Q1 2024-5.1%-6.7%-4.2%
Q4 2023+5.9%+9.4%+17.8%
Q3 2023-3.9%-3.9%-2.9%
Q2 2023-0.5%+0.0%+5.4%
Q1 2023-18.1%-19.6%-16.1%
Q4 2022-1.2%+1.4%+11.7%
Q3 2022+6.5%+9.6%+9.9%
Q2 2022+6.2%+6.5%+9.2%
Q1 2022-6.0%-2.3%+2.8%
Q4 2021-8.0%-5.8%-9.8%
Q3 2021-0.3%+1.4%+2.8%
Q2 2021-1.0%+4.0%+8.9%
Q1 2021-3.7%-3.2%+0.6%
Q4 2020-3.3%-1.2%+8.7%
Q3 2020+2.8%-1.6%+3.4%
Q2 2020+7.0%+9.9%+14.7%
Q1 2020+2.6%-3.2%-7.6%
Q4 2019+9.1%+13.0%+15.4%
Q3 2019-9.1%-8.4%-7.1%
Q2 2019-7.8%-8.8%-17.5%
Q1 2019-2.1%+1.6%+9.3%
Q4 2018+4.1%+3.1%+4.8%
Q3 2018-0.5%-1.5%-1.7%
Q2 2018-11.6%-11.4%-6.3%
Q1 2018-5.7%-6.0%-7.2%
Q4 2017+5.8%+4.9%+8.4%
Q3 2017+3.5%+3.2%-6.2%
Q2 2017-6.8%-7.7%-13.0%
Q1 2017+0.4%-0.0%+8.1%
Q4 2016+1.3%+2.3%+14.7%
Q3 2016-2.2%-0.4%+2.1%
Q2 2016+7.6%
Q1 2016+13.2%
Q4 2015-12.4%
Q3 2015-6.2%
Q2 2015+0.8%
Q1 2015-0.7%
Q4 2014+5.2%
Q3 2014-3.7%
Q2 2014+9.2%
Q1 2014-3.3%
Q4 2013+3.1%
Q3 2013-1.7%
Q2 2013+0.0%
Q1 2013+6.0%
Q4 2012-0.3%
Q3 2012+4.9%
Q2 2012-2.2%
Q1 2012+2.1%
Q3 2009+0.3%
Q4 2011+0.3%
Q3 2011-13.6%
Q2 2011+1.4%
Q1 2010+1.3%
Q1 2011+2.7%
Q2 2010-1.6%
Q4 2008-1.6%
Q4 2010-1.6%
Q4 2009+0.2%
Q3 2010+0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro